Zymeworks
June 24, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
Zymeworks is a global biotechnology company with a partner-driven R&D engine focused on advanced protein engineering, including next-generation antibody-drug conjugates (ADCs) and T cell–engaging therapeutics (TCEs). We leverage proprietary structure-guided modeling and integrated discovery technologies to develop innovative antibody-based therapies for hard-to-treat cancers and other serious diseases. Our clinically validated multispecific antibody (MSAT) and ADC platforms support a diverse pipeline and enable strategic partnerships that provide funding, share risk, and enhance development efficiency. Complementing our R&D approach, our asset and royalty aggregation strategy focuses on generating sustainable revenue from a growing portfolio, including Ziihera® (zanidatamab-hrii) and pasritamig. Together, our platforms, pipeline, and partnership model position Zymeworks as a collaborative partner for advancing differentiated therapeutics and delivering meaningful patient impact.
Company HQ City:
Vancouver
Company HQ State:
British Columbia
Company HQ Country:
Canada
Year Founded:
2003
Lead Product in Development:
Zanidatamab
CEO
Kenneth Galbraith, Chair & CEO
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
9
Exchange
Nasdaq
Ticker
ZYME
When you expect your next catalyst update?
second half of 2026
What is your next catalyst (value inflection) update?
FDA approval for zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}